Comments
Loading...
Instadose Pharma Analyst Ratings and Price Targets | OTC:INSD | Benzinga
Instadose Pharma Corp has a consensus price target of $567.61 based on the ratings of 38 analysts. The high is $1350 issued by HSBC on May 10, 2024<. The low is $100 issued by Deutsche Bank on August 5, 2024. The 3 most-recent analyst ratings were released by New Street Research, Goldman Sachs, and Deutsche Bank on August 6, 2024, August 5, 2024, and August 5, 2024, respectively. With an average price target of $118.33 between New Street Research, Goldman Sachs, and Deutsche Bank, there's an implied 0.21% upside for Instadose Pharma Corp from these most-recent analyst ratings.
Analyst Ratings for Instadose Pharma
| Buy Now | Get Alert | ||||||||
|---|---|---|---|---|---|---|---|---|---|
No data available to display | |||||||||
FAQ
What is the target price for Instadose Pharma (INSD) stock?
There is no price target for Instadose Pharma
What is the most recent analyst rating for Instadose Pharma (INSD)?
There is no analyst for Instadose Pharma
When was the last upgrade for Instadose Pharma (INSD)?
There is no last upgrade for Instadose Pharma
When was the last downgrade for Instadose Pharma (INSD)?
There is no last downgrade for Instadose Pharma.
When is the next analyst rating going to be posted or updated for Instadose Pharma (INSD)?
There is no next analyst rating for Instadose Pharma.
Is the Analyst Rating Instadose Pharma (INSD) correct?
There is no next analyst rating for Instadose Pharma.
Browse analyst ratings and price targets on all stocks.